Generic Name and Formulations:
Nitrofurantoin macrocrystals 25mg, 50mg, 100mg; caps.
Indications for MACRODANTIN:
Take with food. 50–100mg 4 times daily for at least 7 days. Long-term use: 50–100mg at bedtime.
Take with food. <1 month: not recommended. ≥1 month: 5–7mg/kg per day in 4 divided doses for at least 7 days. Long-term use: 1mg/kg per day in 1–2 divided doses.
Anuria, oliguria, CrCl <60mL/min. Neonates <1 month of age. Labor & delivery. Pregnancy at term. History of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin.
Not for treating pyelonephritis or perinephric abscesses. Discontinue if pulmonary reactions, hepatic disorders, or hemolysis occurs. Renal insufficiency; monitor (esp. in elderly). G6PD or Vit. B deficiency. Anemia. Diabetes. Electrolyte imbalance. Monitor renal function and pulmonary condition in long-term use. Debilitated. Pregnancy (Cat.B). Nursing mothers: not recommended.
Reduced absorption by magnesium trisilicate. Uricosurics (eg, probenecid, sulfinpyrazone) may inhibit tubular secretion. May cause false (+) glucose test with Benedict's or Fehling's solution.
Nausea, headache, dizziness, anorexia, alopecia; C. diff-associated diarrhea, pulmonary disorders, hepatic damage, hemolytic anemia, peripheral neuropathy (may be irreversible), anaphylaxis, blood dyscrasias; rare: exfoliative dermatitis, Stevens-Johnson syndrome, aplastic anemia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC